Your browser doesn't support javascript.
loading
Co-occurrence of mutations in NF1 and other susceptibility genes in pheochromocytoma and paraganglioma.
Mellid, Sara; Gil, Eduardo; Letón, Rocío; Caleiras, Eduardo; Honrado, Emiliano; Richter, Susan; Palacios, Nuria; Lahera, Marcos; Galofré, Juan C; López-Fernández, Adriá; Calatayud, Maria; Herrera-Martínez, Aura D; Galvez, María A; Matias-Guiu, Xavier; Balbín, Milagros; Korpershoek, Esther; Lim, Eugénie S; Maletta, Francesca; Lider, Sofia; Fliedner, Stephanie M J; Bechmann, Nicole; Eisenhofer, Graeme; Canu, Letizia; Rapizzi, Elena; Bancos, Irina; Robledo, Mercedes; Cascón, Alberto.
Afiliação
  • Mellid S; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Gil E; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Letón R; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Caleiras E; Histopathology Core Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Honrado E; Anatomical Pathology Service, Hospital of León, León, Spain.
  • Richter S; Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Palacios N; Endocrinology Department, University Hospital Puerta de Hierro, Madrid, Spain.
  • Lahera M; Endocrinology and Nutrition Department, La Princesa University Hospital, Madrid, Spain.
  • Galofré JC; Department of Endocrinology, Clínica Universidad de Navarra, Pamplona, Spain.
  • López-Fernández A; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Calatayud M; Department of Endocrinology and Nutrition, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Herrera-Martínez AD; Endocrinology and Nutrition Service, Reina Sofia University Hospital, Cordoba, Spain.
  • Galvez MA; Endocrinology and Nutrition Service, Reina Sofia University Hospital, Cordoba, Spain.
  • Matias-Guiu X; Department of Pathology, Bellvitge University Hospital, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.
  • Balbín M; Molecular Oncology Laboratory, Instituto Universitario de Oncologia del Principado de Asturias, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Korpershoek E; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands.
  • Lim ES; Department of Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
  • Maletta F; Pathology Unit , Department of Laboratory Medicine, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino, Torino, Italy.
  • Lider S; Endocrinology Department, National Institute of Endocrinology, Bucharest, Romania.
  • Fliedner SMJ; First Department of Medicine, University Medical Center Schleswig-Holstein, Lübeck, Germany.
  • Bechmann N; Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Eisenhofer G; Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Canu L; Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Rapizzi E; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Bancos I; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Robledo M; Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, United States.
  • Cascón A; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Front Endocrinol (Lausanne) ; 13: 1070074, 2022.
Article em En | MEDLINE | ID: mdl-36760809
ABSTRACT

Introduction:

The percentage of patients diagnosed with pheochromocytoma and paraganglioma (altogether PPGL) carrying known germline mutations in one of the over fifteen susceptibility genes identified to date has dramatically increased during the last two decades, accounting for up to 35-40% of PPGL patients. Moreover, the application of NGS to the diagnosis of PPGL detects unexpected co-occurrences of pathogenic allelic variants in different susceptibility genes.

Methods:

Herein we uncover several cases with dual mutations in NF1 and other PPGL genes by targeted sequencing. We studied the molecular characteristics of the tumours with co-occurrent mutations, using omic tools to gain insight into the role of these events in tumour development.

Results:

Amongst 23 patients carrying germline NF1 mutations, targeted sequencing revealed additional pathogenic germline variants in DLST (n=1) and MDH2 (n=2), and two somatic mutations in H3-3A and PRKAR1A. Three additional patients, with somatic mutations in NF1 were found carrying germline pathogenic mutations in SDHB or DLST, and a somatic truncating mutation in ATRX. Two of the cases with dual germline mutations showed multiple pheochromocytomas or extra-adrenal paragangliomas - an extremely rare clinical finding in NF1 patients. Transcriptional and methylation profiling and metabolite assessment showed an "intermediate signature" to suggest that both variants had a pathological role in tumour development.

Discussion:

In conclusion, mutations affecting genes involved in different pathways (pseudohypoxic and receptor tyrosine kinase signalling) co-occurring in the same patient could provide a selective advantage for the development of PPGL, and explain the variable expressivity and incomplete penetrance observed in some patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraganglioma / Feocromocitoma / Neoplasias das Glândulas Suprarrenais Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraganglioma / Feocromocitoma / Neoplasias das Glândulas Suprarrenais Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha